Ticker Hub
CORT — AI Analysis & Sentiment
5 recent AI-generated analyses for CORT. Sentiment and confidence insights updated continuously.
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
Corcept's new, positive overall survival data for Lifyorli significantly strengthens the drug's market position and commercial outlook. This enhanc...
May 29, 2026Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
Corcept's dazucorilant achieved a significant two-year survival benefit in its Phase 2 ALS trial, substantially reducing mortality risk. This break...
Apr 30, 2026Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline
A class action lawsuit alleging misrepresentation regarding FDA warnings for its drug candidate, relacorilant, introduces significant legal and fin...
Mar 12, 2026Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline
The filing of a securities class action lawsuit against Corcept Therapeutics due to alleged misleading statements regarding FDA drug warnings creat...
Feb 26, 2026Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
Corcept Therapeutics announced strong full-year 2025 financial results with significant 2026 revenue guidance and key positive updates for its clin...
Feb 24, 2026